CO6141481A2 - Flavirus seudoinfecciosos y usos de los mismos - Google Patents
Flavirus seudoinfecciosos y usos de los mismosInfo
- Publication number
- CO6141481A2 CO6141481A2 CO08102799A CO08102799A CO6141481A2 CO 6141481 A2 CO6141481 A2 CO 6141481A2 CO 08102799 A CO08102799 A CO 08102799A CO 08102799 A CO08102799 A CO 08102799A CO 6141481 A2 CO6141481 A2 CO 6141481A2
- Authority
- CO
- Colombia
- Prior art keywords
- virus
- protein
- prm
- pseudo
- flaviviridae family
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/18—Togaviridae; Flaviviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24161—Methods of inactivation or attenuation
- C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1.- Un virus seudoinfeccioso de replicación deficiente de la familia Flaviviridae, que comprende: una eliminación en la secuencia de nucleótido que codifica proteína de cápsido (C) de tal manera que la eliminación no interrumpe la secuencia de ARN requerida para la ciclización del genoma, la secuencia de serial para la proteína prM que se requiere para la maduración apropiada de prM/M o una combinación de estos, en donde dicho virus seudoinfeccioso e replicación deficiente solo replica en células que expresan proteína C o C, prM, proteína de la envoltura, proteína C mutada, prM mutada, proteína de la envoltura mutada o combinaciones de estas de un virus de la familia Flaviviridae. 2.- El virus seudoinfeccioso de replicación deficiente de la familia Flaviviridae de la reivindicación 1, en donde dicho virus es un Flavivirus, virus Hepaci o virus Pesti u otras quimeras de dichos virus creados al intercambiar casetes prM-E de otros virus con los casetes prM-E del virus seudoinfeccioso. 3.- El virus seudoinfeccioso de replicación deficiente de la familia Flaviviridae de la reivindicación 2, en donde dicho Flavivirus es un virus de fiebre amarilla, un virus del Nilo del Oeste, un virus de dengue, un virus de la encefalitis vector- garrapata, un virus de la encefalitis Saint Louis, un virus de encefalitis Japonés o un virus de encefalitis del Valle Murray. 4.- El virus seudoinfeccioso de replicación deficiente de la familia Flaviviridae de la reivindicación 3, en donde la secuencia de nucleótido que codifica C de dicho Flavivirus que se elimina codifica los aminoácidos 26 a 100 o una combinación de aminoácidos dentro de los aminoácidos 26 a 100 de la proteína C. 5.- El virus seudoinfeccioso de replicación deficiente de la familia Flaviviridae de la reivindicación 2, en donde dicho Hepacivirus es un virus de Hepatitis C.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77718906P | 2006-02-27 | 2006-02-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6141481A2 true CO6141481A2 (es) | 2010-03-19 |
Family
ID=38438014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO08102799A CO6141481A2 (es) | 2006-02-27 | 2008-09-26 | Flavirus seudoinfecciosos y usos de los mismos |
Country Status (20)
Country | Link |
---|---|
US (2) | US8252574B2 (es) |
EP (1) | EP1991709B1 (es) |
JP (2) | JP5538729B2 (es) |
KR (1) | KR101499750B1 (es) |
CN (1) | CN101454022B (es) |
AP (1) | AP2008004629A0 (es) |
AU (1) | AU2007217352B2 (es) |
BR (1) | BRPI0708332A2 (es) |
CA (1) | CA2643819C (es) |
CO (1) | CO6141481A2 (es) |
CR (1) | CR10323A (es) |
EA (1) | EA016490B1 (es) |
HN (1) | HN2008001324A (es) |
IL (1) | IL193522A (es) |
MY (1) | MY151062A (es) |
NZ (1) | NZ570881A (es) |
SG (1) | SG172642A1 (es) |
UA (1) | UA101597C2 (es) |
WO (1) | WO2007098267A2 (es) |
ZA (1) | ZA200807544B (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101018860B (zh) * | 2004-07-12 | 2013-02-27 | 美国天甲生物医药有限公司 | 黄病毒疫苗 |
CA2643819C (en) | 2006-02-27 | 2018-11-27 | Ilya Frolov | Pseudoinfectious flavivirus and uses thereof |
JP5779352B2 (ja) | 2008-03-14 | 2015-09-16 | サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー | 複製欠損フラビウイルスワクチンおよびワクチンベクター |
EP2408477A4 (en) * | 2009-03-16 | 2013-03-27 | Sanofi Pasteur Biologics Llc | REPLICATION DEFECTS FLAVIVIRUS VACCINE VACCINATORS AGAINST RESPIRATORY SYNZYTIAL VIRUS |
EP2435572B1 (en) | 2009-05-28 | 2017-08-16 | The United States of America, as Represented by The Secretary, Department of Health and Human Services | Antigenic chimeric tick-borne encephalitis virus (tbev)/dengue virus type 4 (den4) recombinant viruses |
BRPI0914507A2 (pt) * | 2009-12-23 | 2012-04-10 | Fundacao Oswaldo Cruz | vacina para lentivìrus baseada em vìrus recombinante vacinal da febre amarela |
WO2012027473A2 (en) * | 2010-08-24 | 2012-03-01 | The University Of North Carolina At Chapel Hill | Immunogenic compositions comprising alphavirus vectored dengue virus e protein antigens |
US9402890B2 (en) * | 2011-02-01 | 2016-08-02 | Uab Research Foundation | Methods and compositions for pseudoinfectious alphaviruses |
CA2896931A1 (en) * | 2012-01-09 | 2013-07-18 | Sanofi Pasteur Biologics, Llc | Purification of flaviviruses |
WO2013138776A1 (en) | 2012-03-16 | 2013-09-19 | Merial Limited | Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g |
US8961995B2 (en) | 2012-09-20 | 2015-02-24 | Uab Research Foundation | Methods and compositions for alphavirus replicons |
HUE043096T2 (hu) * | 2014-06-20 | 2019-07-29 | Univ Aix Marseille | Eljárás egy fertõzõ RNS vírus gyors létrehozására |
EP3031923A1 (en) * | 2014-12-11 | 2016-06-15 | Institut Pasteur | Lentiviral vector-based japanese encephalitis immunogenic composition |
WO2018048869A1 (en) * | 2016-09-06 | 2018-03-15 | Bioventures, Llc | Compositions and methods for generating reversion free attenuated and/or replication incompetent vaccine vectors |
US10590171B2 (en) | 2016-10-28 | 2020-03-17 | The Board Of Regents Of The University Of Texas System | Exosomes and methods of making and using the same |
BR112019016309A2 (pt) * | 2017-02-14 | 2020-03-31 | The Board Of Regents Of The University Of Texas System | Vírus da zika atenuado vivo com deleção 3'utr, vacina contendo o mesmo e uso da mesma |
PE20191842A1 (es) | 2017-05-08 | 2019-12-31 | Gritstone Oncology Inc | Vectores de neoantigeno de alfavirus |
EP3735271A4 (en) | 2018-01-04 | 2022-06-15 | Iconic Therapeutics, Inc. | ANTI-TISSUE FACTOR ANTIBODIES, ANTIBODY DRUG CONJUGATES AND RELATED METHODS |
TW202110870A (zh) | 2019-05-30 | 2021-03-16 | 美商葛利史東腫瘤科技公司 | 經修飾之腺病毒 |
CA3162690A1 (en) | 2019-12-31 | 2021-07-08 | Minoru S. H. Ko | Temperature-based transient delivery of nucleic acids and proteins to cells and tissues |
JP2023519173A (ja) * | 2020-03-09 | 2023-05-10 | アークトゥラス・セラピューティクス・インコーポレイテッド | 免疫応答を誘導するための組成物及び方法 |
CN116438308A (zh) | 2020-08-06 | 2023-07-14 | 磨石生物公司 | 多表位疫苗盒 |
WO2022249757A1 (ja) * | 2021-05-27 | 2022-12-01 | マイキャン・テクノロジーズ株式会社 | 疑似ウイルスを使用した抗体依存性感染増強反応の評価法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002500003A (ja) | 1997-11-28 | 2002-01-08 | ザ・クラウン・イン・ザ・ライト・オヴ・ザ・クイーンズランド・デパートメント・オヴ・ヘルス | フラビウイルスの発現および送達のシステム |
EP1108036B1 (en) | 1998-09-02 | 2010-06-23 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Dengue viruses that are replication defective in mosquitos for use as vaccines |
EP1165842A4 (en) | 1999-03-16 | 2004-07-07 | Dana Farber Cancer Inst Inc | LENTIVIRAL VECTOR SYSTEMS FOR SCREENING LARGE QUANTITIES |
AT410634B (de) | 2001-02-21 | 2003-06-25 | Franz X Dr Heinz | Attenuierte lebendimpfstoffe |
WO2002072803A2 (en) | 2001-03-09 | 2002-09-19 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Subgenomic replicons of the flavivirus dengue |
CA2467397A1 (en) * | 2001-11-26 | 2003-06-05 | The University Of Queensland | Flavivirus vaccine delivery system |
WO2004016794A1 (en) | 2002-08-13 | 2004-02-26 | Akzo Nobel N.V. | Replicons of pestiviruses that do not express c and or e1 protein and infectious viral particles containing same, that can be used in vaccines |
WO2004022761A1 (en) | 2002-09-03 | 2004-03-18 | Oxford Biomedica (Uk) Limited | Retroviral vector and stable packaging cell lines |
JP5250179B2 (ja) * | 2002-11-08 | 2013-07-31 | ザ アドミニストレイターズ オブ ザ テューレイン エデュケイショナル ファンド | フラビウイルス融合インヒビター |
US6943015B2 (en) | 2002-12-12 | 2005-09-13 | Ilya Frolov | Large scale production of packaged alphavirus replicons |
WO2004072274A1 (fr) | 2003-01-30 | 2004-08-26 | Shanghai Tengen Biomedical Co., Ltd. | Vaccin a base de pseudoparticules virales ayant comme support un replicon de recombinaison du virus de la dengue |
CA2520538C (en) * | 2003-03-31 | 2014-04-29 | F. Hoffmann-La Roche Ag | Compositions and methods for detecting certain flaviviruses, including members of the japanese encephalitis virus serogroup |
AU2003902842A0 (en) | 2003-06-06 | 2003-06-26 | The University Of Queensland | Flavivirus replicon packaging system |
CN101018860B (zh) | 2004-07-12 | 2013-02-27 | 美国天甲生物医药有限公司 | 黄病毒疫苗 |
CA2643819C (en) | 2006-02-27 | 2018-11-27 | Ilya Frolov | Pseudoinfectious flavivirus and uses thereof |
-
2007
- 2007-02-27 CA CA2643819A patent/CA2643819C/en active Active
- 2007-02-27 SG SG2011038668A patent/SG172642A1/en unknown
- 2007-02-27 EA EA200870304A patent/EA016490B1/ru not_active IP Right Cessation
- 2007-02-27 CN CN2007800150079A patent/CN101454022B/zh not_active Expired - Fee Related
- 2007-02-27 WO PCT/US2007/004957 patent/WO2007098267A2/en active Application Filing
- 2007-02-27 AU AU2007217352A patent/AU2007217352B2/en not_active Ceased
- 2007-02-27 US US11/711,532 patent/US8252574B2/en active Active
- 2007-02-27 BR BRPI0708332-7A patent/BRPI0708332A2/pt not_active IP Right Cessation
- 2007-02-27 AP AP2008004629A patent/AP2008004629A0/xx unknown
- 2007-02-27 KR KR1020087023511A patent/KR101499750B1/ko not_active IP Right Cessation
- 2007-02-27 JP JP2008556467A patent/JP5538729B2/ja not_active Expired - Fee Related
- 2007-02-27 EP EP07751696.1A patent/EP1991709B1/en active Active
- 2007-02-27 MY MYPI20083286 patent/MY151062A/en unknown
- 2007-02-27 ZA ZA200807544A patent/ZA200807544B/xx unknown
- 2007-02-27 NZ NZ570881A patent/NZ570881A/en not_active IP Right Cessation
- 2007-02-27 UA UAA200811510A patent/UA101597C2/uk unknown
-
2008
- 2008-08-18 IL IL193522A patent/IL193522A/en not_active IP Right Cessation
- 2008-08-27 HN HN2008001324A patent/HN2008001324A/es unknown
- 2008-09-25 CR CR10323A patent/CR10323A/es unknown
- 2008-09-26 CO CO08102799A patent/CO6141481A2/es unknown
-
2012
- 2012-07-28 US US13/561,002 patent/US9273288B2/en active Active
-
2013
- 2013-12-24 JP JP2013264813A patent/JP2014121324A/ja not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
CR10323A (es) | 2009-01-29 |
WO2007098267A3 (en) | 2008-11-20 |
AU2007217352A1 (en) | 2007-08-30 |
HN2008001324A (es) | 2010-10-29 |
MY151062A (en) | 2014-03-31 |
IL193522A (en) | 2014-05-28 |
ZA200807544B (en) | 2009-11-25 |
CN101454022A (zh) | 2009-06-10 |
JP2009528032A (ja) | 2009-08-06 |
CA2643819C (en) | 2018-11-27 |
BRPI0708332A2 (pt) | 2011-05-24 |
JP5538729B2 (ja) | 2014-07-02 |
CA2643819A1 (en) | 2007-08-30 |
JP2014121324A (ja) | 2014-07-03 |
AP2008004629A0 (en) | 2008-10-31 |
EP1991709A4 (en) | 2009-10-21 |
US8252574B2 (en) | 2012-08-28 |
US20090155301A1 (en) | 2009-06-18 |
EP1991709B1 (en) | 2017-01-25 |
EA016490B1 (ru) | 2012-05-30 |
AU2007217352B2 (en) | 2013-09-26 |
EP1991709A2 (en) | 2008-11-19 |
KR20090008193A (ko) | 2009-01-21 |
KR101499750B1 (ko) | 2015-03-06 |
UA101597C2 (uk) | 2013-04-25 |
WO2007098267A2 (en) | 2007-08-30 |
CN101454022B (zh) | 2013-09-04 |
NZ570881A (en) | 2011-09-30 |
EA200870304A1 (ru) | 2009-02-27 |
IL193522A0 (en) | 2009-05-04 |
SG172642A1 (en) | 2011-07-28 |
US9273288B2 (en) | 2016-03-01 |
US20130023031A1 (en) | 2013-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6141481A2 (es) | Flavirus seudoinfecciosos y usos de los mismos | |
Friebe et al. | Sequences in the 5′ nontranslated region of hepatitis C virus required for RNA replication | |
Grassmann et al. | Assignment of the multifunctional NS3 protein of bovine viral diarrhea virus during RNA replication: an in vivo and in vitro study | |
Funk et al. | RNA structures required for production of subgenomic flavivirus RNA | |
Pugachev et al. | High fidelity of yellow fever virus RNA polymerase | |
Tilgner et al. | The flavivirus-conserved penta-nucleotide in the 3′ stem-loop of the West Nile virus genome requires a specific sequence and structure for RNA synthesis, but not for viral translation | |
Lohmann et al. | Mutations in hepatitis C virus RNAs conferring cell culture adaptation | |
Pijlman et al. | A highly structured, nuclease-resistant, noncoding RNA produced by flaviviruses is required for pathogenicity | |
Liu et al. | Dengue virus subgenomic RNA induces apoptosis through the Bcl-2-mediated PI3k/Akt signaling pathway | |
Deas et al. | Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication | |
Clyde et al. | The capsid-coding region hairpin element (cHP) is a critical determinant of dengue virus and West Nile virus RNA synthesis | |
Ray et al. | West Nile virus 5′-cap structure is formed by sequential guanine N-7 and ribose 2′-O methylations by nonstructural protein 5 | |
Salas-Benito et al. | Viral interference and persistence in mosquito‐borne flaviviruses | |
Lackner et al. | Temporal modulation of an autoprotease is crucial for replication and pathogenicity of an RNA virus | |
Nomaguchi et al. | De novo synthesis of negative-strand RNA by Dengue virus RNA-dependent RNA polymerase in vitro: nucleotide, primer, and template parameters | |
Khromykh et al. | cis-and trans-acting elements in flavivirus RNA replication | |
DE602005026545D1 (de) | Modifizierte genomische rna des menschlichen hepatitis-c-virus mit autonomer replikationskompetenz | |
Tilgner et al. | Structure and function of the 3′ terminal six nucleotides of the West Nile virus genome in viral replication | |
Zou et al. | Exclusion of West Nile virus superinfection through RNA replication | |
Riedel et al. | Characterization of essential domains and plasticity of the classical swine fever virus core protein | |
Tajima et al. | Restoration of replication-defective dengue type 1 virus bearing mutations in the N-terminal cytoplasmic portion of NS4A by additional mutations in NS4B | |
Teramoto et al. | Serotype-specific interactions among functional domains of dengue virus 2 nonstructural proteins (NS) 5 and NS3 are crucial for viral RNA replication | |
Teramoto et al. | Substitution of NS5 N-terminal domain of dengue virus type 2 RNA with type 4 domain caused impaired replication and emergence of adaptive mutants with enhanced fitness | |
McGee et al. | Stability of yellow fever virus under recombinatory pressure as compared with chikungunya virus | |
Myers et al. | Efficient translation initiation is required for replication of bovine viral diarrhea virus subgenomic replicons |